
Gilead Sciences (GILD) Stock Forecast & Price Target
Gilead Sciences (GILD) Analyst Ratings
Bulls say
Gilead Sciences is experiencing a positive outlook driven by anticipated revenue growth from its oncology portfolio, particularly following the expected approval of Trodelvy for 1L mTNBC, with revenue estimates raised to over $1.0 billion at peak based on strong quarterly sales of Livdelzi and the potential expansion of its label. The company has also achieved a milestone in payer coverage, hitting a 90% goal ahead of schedule, which strengthens its market position amid competitive challenges. Additionally, solid revenue growth in the HIV franchise, coupled with disciplined operating expenses and improving operating margins, further supports Gilead's favorable financial trajectory.
Bears say
Gilead Sciences's outlook appears negative due to the significant downward revisions in revenue guidance for its antiviral drug Veklury, which is projected to generate only $1.0 billion in FY25, down from the previous estimate of $1.4 billion, with a further decline to $600 million anticipated in 2026. The company's cell therapy franchise has also encountered competitive challenges, leading to a 6% year-over-year decline in revenue to $458 million and a forecasted revenue drop of 10% in 2026. Additionally, ongoing policy-related headwinds and the decreasing relevance of Veklury's sales to total revenues cast further uncertainty on Gilead's financial trajectory.
This aggregate rating is based on analysts' research of Gilead Sciences and is not a guaranteed prediction by Public.com or investment advice.
Gilead Sciences (GILD) Analyst Forecast & Price Prediction
Start investing in Gilead Sciences (GILD)
Order type
Buy in
Order amount
Est. shares
0 shares